Publication at Faculty of Physical Education and Sport, First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové |
2010
Abstract
The metabolic syndrome is a cluster of symptoms that function as risk factors for cardiovascular disease (CVD), and its key components—diabetes, dyslipidemia, and hypertension—form a lethal combination. The incidence of obesity and other components of the metabolic syndrome is now at epidemic proportions, and current lifestyle trends suggest that it will continue to increase worldwide.
The pharmacotherapy of atherogenic dyslipidemia should often use a combined hypolipidemic treatment. The basis is a statin.
The combination of hypolipidemic drugs is indicated when the treatment goal is not accomplished. The possible combinations include namely fibrate and niacin.